Arrowhead Pharmaceuticals (ARWR) said Thursday it has presented preclinical data supporting two RNA-interference-based investigational therapeutics it is developing, with the potential to reduce body weight and fat mass and preserve lean muscle mass compared with currently approved obesity therapies.

Data from its ARO-INHBE candidate preclinical results showed a 19% suppression in body weight gain relative to vehicle controls, while data from its ARO-ALK7 candidate preclinical results showed a 39% suppression, the company said.

Arrowhead is currently conducting phase 1/2 clinical studies of the two candidates. The company expects initial data from its ARO-INHBE study year-end 2025, and anticipates dosing in the ARO-ALK7 study to begin in the second quarter with initial data from the single-ascending dose portion of the study possible also by year-end 2025.

The company presented the data at the RNA Leaders Europe Congress 2025 held March 4-6 in Basel, Switzerland.

Price: 16.89, Change: -0.46, Percent Change: -2.65